WO2003026673A1 - Modulation du stockage de vitamines - Google Patents

Modulation du stockage de vitamines Download PDF

Info

Publication number
WO2003026673A1
WO2003026673A1 PCT/AU2002/001321 AU0201321W WO03026673A1 WO 2003026673 A1 WO2003026673 A1 WO 2003026673A1 AU 0201321 W AU0201321 W AU 0201321W WO 03026673 A1 WO03026673 A1 WO 03026673A1
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
tocopherol
phosphate derivative
phosphate
subject
Prior art date
Application number
PCT/AU2002/001321
Other languages
English (en)
Inventor
Simon Michael West
David Kannar
Original Assignee
Vital Health Sciences Pty Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/AU2001/001206 external-priority patent/WO2002026238A1/fr
Priority claimed from AU2002951045A external-priority patent/AU2002951045A0/en
Application filed by Vital Health Sciences Pty Ltd. filed Critical Vital Health Sciences Pty Ltd.
Priority to CA002458279A priority Critical patent/CA2458279A1/fr
Priority to BR0212887-0A priority patent/BR0212887A/pt
Priority to AU2002333019A priority patent/AU2002333019B2/en
Priority to US10/487,743 priority patent/US20040241225A1/en
Priority to JP2003530308A priority patent/JP2005515969A/ja
Priority to MXPA04001779A priority patent/MXPA04001779A/es
Priority to EP02799356A priority patent/EP1429782A4/fr
Publication of WO2003026673A1 publication Critical patent/WO2003026673A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the invention relates to modulating vitamin levels in animals, particularly levels of endogenous storage forms of tocopherol (Vitamin E), retinol (Vitamin A) or Vitamin K1 by administration of phosphate derivatives.
  • tocopherol and tocopheryl phosphate Whilst the following discussion concerns tocopherol and tocopheryl phosphate (TP), it is to be understood that this is merely illustrative and that the invention is not limited to tocopherol or TP but that the invention also similarly relates to retinol and vitamin K1 and their storage and transport forms.
  • Vitamin E is widely recognised as an anti-oxidant of considerable biological importance. It is a potent free radical scavenger with a vital role in the maintenance of cellular integrity through its capacity to protect the polyunsatu rated fatty acyl moieties of phospholipids in biological membranes and plasma lipoproteins.
  • Vitamin E consists of the group of isoprenoids know as 'tocopherols' which provide benefits to the health and well-being of humans and animals.
  • Several different tocopherols having Vitamin E activity are known, the most active and abundant being ⁇ -tocopherol.
  • the supplements should have adequate stability, solubility, permeability and bioavailability.
  • Free tocopherol is not stable and therefore not suitable as a bioavailable delivery form of Vitamin E.
  • derivatisation has long been recognised as an important means of increasing stability and bioavailability of tocopherol, but it is generally accepted that absorption of these derivatives has still been low.
  • Tocopherol organic esters such as tocopheryl acetate or tocopheryl succinate are examples of such derivatised species which are currently in widespread commercial use. These esters are cheap to produce and more stable than free tocopherol.
  • tocopherol derivatives should be capable of converting to the biologically active species after they have been absorbed into the systemic circulation of a human or animal subject.
  • Formulators believed that the free form of tocopherol was biologically active and thus believed that when the pancreatic esterase and lipase activity released free tocopherol from the organic esters of tocopherol in the small intestine lumen, the body's levels of Vitamin E were increased.
  • Tocopherol acetate has been favoured as a Vitamin E dietary supplement of the prior art because it reportedly causes an immediate, readily measurable increase in plasma free tocopherol levels.
  • Formulators who have been attempting to increase the water solubility of tocopherol derivatives have prepared formulations containing TP as it is much more water soluble than organic esters of tocopherol. While TP has been used as a water soluble source of Vitamin E in vitro, it has not previously been commonly • used as a suitable in vivo source of Vitamin E because the phosphate group is a substrate of phosphorylases, is resistant to passive transport, and therefore considered to interfere with absorption.
  • Vitamin E supplements containing either tocopheryl acetate or tocopheryl phosphate have aimed to provide a recommended daily intake of 7 - 15 mg/day per person of free tocopherol in the body. Supplements have contained 200 - 600 mg as this amount is considered to be innocuous in adult humans, although there is limited evidence of this.
  • Paradoxically, as well as being a potent free radical scavenger ⁇ -tocopherol is also a pro-oxidant and a potential source of free radicals which would cause damage to the body. Free tocopherol is pro-oxidant at high concentrations so it is unlikely that this is the biological storage or transport form within the body.
  • tocopherol, retinol and vitamin K1 are their respective phosphate derivatives. These phosphate derivatives are not typically a source of free radicals. Surprisingly, the present inventors have found that administering phosphate derivatives of tocopherol, retinol or vitamin K1 to an animal can provide therapeutically useful levels of tocopherol, retinol or vitamin K1 in storage and transport forms.
  • the present invention provides a method for increasing levels of a storage form of a vitamin selected from the group consisting of tocopherol, retinol, vitamin K1 and mixtures thereof in a target tissue of a subject, the method comprising administering to the subject an effective amount of a phosphate derivative of the vitamin so as to cause an accumulation of stored vitamin in the target tissue.
  • the vitamin is tocopherol.
  • the subject is an animal, more preferably the animal is a human.
  • the target tissue is liver because it is the storage organ of preference and the generation site of lipoprotein cholesterol. It is also known that there is Vitamin E activity in the skin and TP is important in skin metabolism. Vitamin E may also be important for adipose tissue where it may protect against degradation of unsaturated fats. Vitamin E may also be important in the brain.
  • the increased levels of the stored vitamin(s) result in potentially therapeutic levels of the vitamin(s) in the animal.
  • the present invention is particularly suitable for increasing the storage levels of the vitamins to be of therapeutic value.
  • Increased levels of vitamins, particularly tocopherol can have uses in the treatment of inflammatory diseases such as, but not limited to, coronary diseases, atherosclerosis and diabetes and a number of diseases affected by tocopherol, such as cancer where tocopherol affects cell adhesion, and foetal development.
  • inflammatory diseases such as, but not limited to, coronary diseases, atherosclerosis and diabetes
  • tocopherol a number of diseases affected by tocopherol, such as cancer where tocopherol affects cell adhesion, and foetal development.
  • vitamin levels may assist treatment of alzheimers.
  • Therapeutic levels of the vitamins would typically be in the order of at least about 50% increase of the levels usually stored in healthy or normal tissue. Preferably, the levels are increased by at least about 100%, more preferably at least about 200%, that is, about 2 to 3 times normal plasma or tissue levels.
  • higher levels of vitamins can then be released in a number of ways to provide potentially higher doses of biologically available vitamin to organs or tissue in the body as required.
  • the present invention may also be suitable for treating or overcoming problems with subjects unable to acquire or utilise vitamins by normal dietary uptake or processing.
  • the ability to increase storage levels may also be useful to overcome consequences of periods of low or poor dietary intake.
  • Tocopherol is used in three forms in the body, being
  • the increased storage forms acts as a source of tocopherol, retinol or vitamin K1 to tissue, organs or cells of the subject.
  • the present inventors have found that at least about 3 mg/kg (at least about 240 mg in an 80 kg adult), typically from about 3 to 50 mg/kg of the phosphate derivative of the vitamin is required to increase storage levels to a beneficial amount. More preferably, 3 to 30 mg/kg is provided. More preferably, at least 10 mg/kg body mass of tocopherol provided orally as tocopheryl phosphate has been found suitable to achieve a level of 68% absolute bioavailability. This is significantly more than the recommended daily intake (RDI) of 7-15 mg/day for a normal person.
  • RDI recommended daily intake
  • the dosage may be achieved by administering the phosphate derivative of the vitamin(s) in one dose or may be administered over a period of minutes, hours or days to achieve the required stored amount of the vitamin(s).
  • the phosphate derivative of the vitamin can be given by any suitable route such as orally or parenterally.
  • the present invention provides a method for alleviating or treating a subject suffering a condition responsive to a vitamin treatment, the method comprising administering to a subject in need of such treatment an amount of a phosphate derivative of the vitamin selected from the group consisting of tocopherol, retinol, vitamin K1 and mixtures thereof effective to cause an accumulation of a therapeutic amount of tocopherol, retinol vitamin K1 or a mixture thereof in a tissue of the subject.
  • the conditions expected to be responsive to a vitamin treatment are inflammatory diseases such as, but not limited to, coronary diseases, artherosclerosis and diabetes and a number of diseases affected by tocopherol, such as cancer where tocopherol affects cell adhesion, and foetal development.
  • inflammatory diseases such as, but not limited to, coronary diseases, artherosclerosis and diabetes and a number of diseases affected by tocopherol, such as cancer where tocopherol affects cell adhesion, and foetal development.
  • the vitamin is tocopherol.
  • the subject is an animal, more preferably the animal is a human.
  • the target tissue is liver as this tissue can be used to indicate that there are adequate stores for the various ubiquitous metabolic activities in different tissues.
  • the phosphate derivative of the vitamin can be given by any suitable route such as orally or parenterally.
  • the present inventors have found that at least about 3 mg/kg (at least about 240 mg in an 80 kg adult), typically from about 3 to 30 mg/kg of the phosphate derivative of the vitamin is required to increase storage levels to a beneficial amount which can result in therapeutic levels of the vitamin(s). More preferably, about 10 mg/kg body mass of tocopherol provided orally as tocopheryl phosphate has been found suitable to achieve a level of 68% absolute bioavailability. This is significantly more than the recommended daily intake (RDI) of 7-10 mg/day for a normal person.
  • RDI recommended daily intake
  • the present invention provides use of an effective amount of a phosphate derivative of a vitamin selected from the group consisting of tocopherol, retinol, vitamin K1 and mixtures thereof in the manufacture of a supplement for causing an accumulation of stored vitamin in the target tissue of an animal.
  • the present invention provides use of an effective amount of a phosphate derivative of a vitamin selected from the group consisting of tocopherol, retinol, vitamin K1 and mixtures thereof in the manufacture of a medicament for alleviating or treating a subject suffering a condition responsive to a vitamin treatment.
  • phosphate derivatives of the vitamin is used herein to refer to the acid forms of phosphorylated tocopherol, retinol or vitamin K1 , salts of the phosphates including metal salts such as sodium, magnesium, potassium and calcium and any other derivative where the phosphate proton is replaced by other substituents such as ethyl or methyl groups or phosphatidyl groups.
  • Phosphatidyl derivatives are amino alkyl derivatives of organic phosphates. These derivatives may be prepared from amines having a structure of R ⁇ R 2 N(CH 2 ) n OH wherein n is an integer between 1 and 6 and Ri and R 2 may be either H or short alkyl chains with 3 or less carbons. Ri and R 2 may be the same or different.
  • the phosphatidyl derivatives are prepared by displacing the hydroxyl proton of the electron transfer agent with a phosphate entity that is then reacted with an arnine, such as ethanolamine or N,N' dimethylethanolamine, to generate the phosphatidyl derivative of the electron transfer agent.
  • a basic solvent such as pyridine or triethylamine with phosphorous oxychlohde to prepare the intermediate which is then reacted with the hydroxy group of the amine to produce the corresponding phosphatidyl derivative, such as P cholyl P tocopheryl dihydrogen phosphate.
  • complexes of phosphate derivatives of the vitamins may also be utilized where additional properties such as improved stability or deliverability may be useful.
  • the term "complexes of phosphate derivatives of the vitamin” refers to the reaction product of one or more phosphate derivatives of tocopherol, retinol or vitamin K1 and mixtures thereof with one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids as disclosed in international patent application no PCT/AU01/01476.
  • the preferred complexing agents are selected from the group consisting of arginine, lysine and tertiary substituted amines, such as those according to the following formula:
  • R 1 is chosen from the group comprising straight or branched chain mixed alkyl radicals from C6 to C22 and carbonyl derivatives thereof;
  • R 2 and R 3 are chosen independently from the group comprising H, CH 2 COOX, CH 2 CHOHCH 2 SO 3 X, CH 2 CHOHCH 2 OP0 3 X, CH 2 CH 2 COOX, CH 2 COOX, CH 2 CH 2 CHOHCH 2 SO 3 X or CH 2 CH 2 CHOHCH 2 OPO3X and X is H, Na, K or alkanolamine provided R 2 and R 3 are not both H; and wherein when R 1 is RCO then R 2 may be CH 3 and R 3 may be (CH 2 CH 2 )N(C 2 H 4 OH)-H 2 CHOPO 3 or R 2 and R 3 together may be N(CH 2 ) 2 N(C 2 H 4 OH)CH 2 COO-.
  • Preferred complexing agents include arginine, lysine or lauryliminodipropionic acid ' where complexation occurs between the alkaline nitrogen center and the phosphoric acid ester to form a stable complex.
  • the administration of phosphate derivatives of the vitamin to provide a 'therapeutic effect' includes administration to achieve a curative, preventative or other beneficial health effect.
  • administration to a subject may be undertaken to treat a deficiency of the vitamin, to ameliorate or cure a disease or disorder, to ameliorate or remove the symptoms of the disease or disorder, or to increase the subject's plasma and tissue level of the vitamin to provide a beneficial effect.
  • the phosphate derivative of the vitamin may be administered to humans or animals through a variety of dose forms such as supplements, enteral feeds, parenteral dose forms, suppositories, nasal delivery forms, dermal delivery including patches, creams, and any other delivery system capable of supplementing the natural storage and transport form of the electron transfer agent.
  • dose forms such as supplements, enteral feeds, parenteral dose forms, suppositories, nasal delivery forms, dermal delivery including patches, creams, and any other delivery system capable of supplementing the natural storage and transport form of the electron transfer agent.
  • the phosphate derivative of the vitamin may be administered by an orally or parenterally administered dose form.
  • these include, tablets, powders, chewable tablets, capsules, oral suspensions, suspensions, emulsions or fluids, children's formulations, enteral feeds, nutraceuticals, and functional foods.
  • the dose form may further include any additives routinely used in preparation of that dose form such as starch or polymeric binders, sweeteners, coloring agents, emulsifiers, coatings and the like.
  • additives routinely used in preparation of that dose form such as starch or polymeric binders, sweeteners, coloring agents, emulsifiers, coatings and the like.
  • Other suitable additives will be readily apparent to those skilled in the art.
  • the dose form has an enteric coating as disclosed in international patent application PCT/AU01/01206.
  • the dose form is a topical formulation as disclosed in international patent application PCT/AU02/01003.
  • endogenous refers to a vitamin occurring in the body as the result of ingestion from a diet with no supplementation of the vitamin or its derivatives, and where only typical metabolic processes transform the dietary vitamin.
  • Figure 1 Calibration curve for TP vs T 2 P using ESMS.
  • Figure 2 GCMS of methylated liver extract and TP standard.
  • Figure 3 Example of TP ESMS spectra.
  • Figure 4 Example of liver extract ESMS spectra.
  • ⁇ -tocopheryl phosphate the monophosphate ester of ⁇ -tocopherol, ⁇ - tocopheryl phosphate, is present in significant quantities (8-147 ⁇ g/g) in a range of biological tissues.
  • ⁇ -Tocopheryl phosphate is resistant to oxidation and is thus inactive as an anti-oxidant; it is also resistant to acid and alkaline hydrolysis so that it cannot be detected by the standard assays for Vitamin E.
  • the discovery of this storage form of Vitamin E heralds the need for a reassessment of the role of this essential vitamin in the body.
  • TP as a nascent storage form is not a source of free radicals in marked contrast to free tocopherol which is an excellent source of undesirable free radicals or pro-oxidant at high concentrations.
  • Oxidation with active phosphorylation of adenosine diphosphate for example, is known suggesting that ⁇ -tocopheryl phosphate may be a reducing agent capable of producing phosphorylated secondary messengers. This would account for the non-antioxidant roles ascribed to tocopherol.
  • ⁇ -tocopheryl phosphate is stored in the lipoprotein environment in association with a lipophilic protein or as a glycerophosphate derivative.
  • the proximity of a free radical or the generation of an oxidative environment stimulates the dephosphorylation of ⁇ - tocopheryl phosphate and the release of free ⁇ -tocopherol.
  • excess antioxidant, ( ⁇ -tocopherol) is drawn back into storage by phosphorylation. This conservative strategy avoids pro-oxidation.
  • This proposed mode of action for ⁇ -tocopheryl phosphate may also apply to other lipophilic bioactive compounds and provide a new explanation for its function in vivo.
  • Vitamin E the storage form of Vitamin E was investigated in various tissues.
  • the standard analytical methodology for the detection of ⁇ -tocopherol in tissue samples and foodstuffs normally includes a hydrolysis step as part of the extraction process.
  • the hydrolysis ensures that ⁇ -tocopheryl esters, such as added ⁇ -tocopherol acetate, are converted to free ⁇ -tocopherol prior to analysis.
  • ⁇ -tocopheryl phosphate is resistant to all of the alkaline and acid hydrolysis conditions encountered in these procedures and is consequently not included with free ⁇ -tocopherol in typical analyses. Indeed, refluxing ⁇ -tocopheryl phosphate under strongly alkaline or acidic conditions for extended periods in excess of 24 hours does not lead to any cleavage of the phosphate bond. We have been unable to discover conditions under which ⁇ -tocopheryl phosphate can be hydrolysed to yield free ⁇ -tocopherol. ⁇ -Tocopheryl phosphate has also proven to be resistant to oxidation and does not give a positive colour test under conditions of the standard colorimetric ⁇ -tocopherol analysis.
  • GCMS Gas chromatography/mass spectrometry
  • ⁇ -tocopheryl phosphate could not be detected, which suggests that it is associated with a protein or other some other compound; for example, the ⁇ -tocopheryl phosphate may be present as a glycerophosphate or similar ester, and that hydrolysis is required to liberate free ⁇ -tocopheryl phosphate.
  • the hydrolysate was then washed with hexane to remove all of the organic soluble material. Free ⁇ -tocopherol was removed at this stage and could be readily analysed using standard techniques; ⁇ -tocopheryl phosphate was present as the potassium salt, and being water soluble was not extracted. Acidification of the aqueous layer converted the ⁇ -tocopheryl phosphate to the free acid, which was readily extracted into hexane.
  • ⁇ -tocopheryl phosphate has been detected in pig, guinea pig, chicken and rat liver, and in human, pig and guinea pig adipose tissue. Liver and adipose have been reported to be the two main storage sites for ⁇ -tocopherol and it is therefore not surprising that ⁇ -tocopheryl phosphate is also present in these tissues. Our results indicate that the ⁇ -tocopheryl phosphate makes up a significant proportion of the total ⁇ -tocopherol present. TP has hitherto been considered to be unable to be deposited directly in tissues where it can remain as a storage form of tocopherol. However, the following example illustrates the detection of ingested TP in human and animal tissue.
  • T 2 P ditocopheryl phosphate
  • the methylated liver extract and TP standard were analysed using a Shimadsu GCMS-QP5000 Gas Chromatograph Mass Spectrometer incorporating a Shimadsu AOC-20i Auto Injector.
  • One ⁇ l of sample was injected onto a 15m SGE.BP1 capillary column, with a thickness of 0.25 ⁇ m and an internal diameter of 0.25 mm utilising a temperature program from 260°C up to 300°C ramping at 3°C per minute.
  • the injector and interface temperatures were both set at 300°C.
  • the carrier gas used was helium, the column inlet pressure was set at 156 kPa and the total flow was 144 ml/min, thus presenting a column flow of 2.4 ml/min with a linear velocity of 86.5 cm/sec.
  • the samples were run in split mode with a split ratio of 56:1.
  • the detector gain for this acquisition was set at 1.5 kVolts.
  • TP in Rat Liver Non-treated rat livers were used to extract, detect and quantitate the amount of naturally occurring TP.
  • Fresh livers from Sprague-dawley and Wistar rats (aged between 10 to 11 weeks old, weighing approximately 120-180 grams) were used for each extraction.
  • TP has also been detected in human abdominal fat, Guinea Pig and rat adipose tissue, porcine and guinea pig liver of humans and animals which have not been administered TP.
  • Table 1 outlines the quantity of TP detected in each organ.
  • This example investigates whether tocopheryl phosphate levels in storage sites are increased after tocopheryl acetate and tocopheryl phosphate were administered.
  • Livers were be extracted according to the method below. The extracts will be analyzed and quantitated for TP ( ⁇ g) content by ESMS. Any tissue samples left over at the end of the study was kept frozen at -80 °C. Liver extraction
  • liver was homogenized in 10 ml dichloromethane (analytical grade). Add 0.1 mg tocopheryl diphosphate (internal standard). Homogenize sample for 2 min, centrifuge and remove upper layer and evaporate under nitrogen. Add 9 ml KOH (2M) and stir for 1 hr at room temperature (or 20 min at 80 C). Add 10 ml hexane, shake and remove upper layer. Add 10 ml HCI (2M) and shake. Add 10 ml hexane to the solution and shake and remove upper layer. Evaporate top layer to dryness.
  • TP was administered by IV to provide a value for absolute bioavailability.
  • the amounts in brackets are percentages when compared with the IV value.
  • TP has higher bioavailability than tocopheryl acetate because the transformation to phosphate is not required
  • Table 4 shows the results of TP analysis in chicken fat, muscle and eggs.
  • TP farnesoid TP

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une méthode permettant d'augmenter les taux de vitamine stockée pour une vitamine sélectionnée dans le groupe comprenant le tocophérol, le rétinol, la vitamine K1 et des mélanges de ceux-ci, dans un tissu cible d'un sujet. Cette méthode consiste à administrer au sujet une dose efficace d'un dérivé phosphate de cette vitamine de manière à provoquer une accumulation de vitamine stockée dans le tissu cible.
PCT/AU2002/001321 2001-09-26 2002-09-26 Modulation du stockage de vitamines WO2003026673A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002458279A CA2458279A1 (fr) 2001-09-26 2002-09-26 Modulation du stockage de vitamines
BR0212887-0A BR0212887A (pt) 2001-09-26 2002-09-26 Método para aumentar nìveis de uma forma de armazenagem de uma vitamina e uso de uma quantidade eficaz de um derivado de fosfato de uma vitamina
AU2002333019A AU2002333019B2 (en) 2001-09-26 2002-09-26 Modulation of vitamin storage
US10/487,743 US20040241225A1 (en) 2001-09-26 2002-09-26 Modulation of vitamin storage
JP2003530308A JP2005515969A (ja) 2001-09-26 2002-09-26 ビタミン貯蔵の調節
MXPA04001779A MXPA04001779A (es) 2001-09-26 2002-09-26 Modulacion de almacenamiento de vitamina.
EP02799356A EP1429782A4 (fr) 2001-09-26 2002-09-26 Modulation du stockage de vitamines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/AU2001/001206 WO2002026238A1 (fr) 2000-09-26 2001-09-26 Supplements a base de derive phosphate
AUPCT/AU01/01206 2001-09-26
AU2002951045 2002-08-27
AU2002951045A AU2002951045A0 (en) 2002-08-27 2002-08-27 Method of supplementing nascent endogenous storage forms

Publications (1)

Publication Number Publication Date
WO2003026673A1 true WO2003026673A1 (fr) 2003-04-03

Family

ID=25613914

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2002/001321 WO2003026673A1 (fr) 2001-09-26 2002-09-26 Modulation du stockage de vitamines

Country Status (5)

Country Link
EP (1) EP1429782A4 (fr)
JP (1) JP2005515969A (fr)
CA (1) CA2458279A1 (fr)
MX (1) MXPA04001779A (fr)
WO (1) WO2003026673A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064831A1 (fr) * 2003-01-17 2004-08-05 Vital Health Sciences Pty Ltd Composes possedant des proprietes antiproliferatives
WO2006092025A1 (fr) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Composés ayant des propriétés d’abaissement des lipides
WO2006092024A1 (fr) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Composés ayant des propriétés anticancéreuses
EP1720551A1 (fr) * 2004-03-03 2006-11-15 Vital Health Sciences Pty Ltd. Formulations alcaloides
US20090004166A1 (en) * 2004-08-03 2009-01-01 Simon Michael West Carrier For Enternal Administration
WO2011094822A1 (fr) * 2010-02-05 2011-08-11 Phosphagenics Limited Composition de support
US8841342B2 (en) 2002-08-09 2014-09-23 Vital Health Sciences Pty. Ltd. Carrier
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
US11753435B2 (en) 2016-12-21 2023-09-12 Avecho Biotechnology Limited Process

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
WO1993015731A1 (fr) * 1992-02-14 1993-08-19 Robert Lamb Derives de phosphate de vitamine e pour la protection des cellules
EP0684043A1 (fr) * 1994-04-28 1995-11-29 Senju Pharmaceutical Co., Ltd. Composition thérapeutique pour les altéreations de la cornée contenant un diester de l'acide phosphonique
US5603949A (en) * 1991-08-01 1997-02-18 Lvmh Recherche Use of a tocopherol phosphate or one of its derivatives, for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
US5643597A (en) * 1991-08-01 1997-07-01 Lvmh Recherche Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
EP0845216A1 (fr) * 1996-11-27 1998-06-03 Showa Denko Kabushiki Kaisha Composition destinée à être administrée aux animaux et contenant un phosphate de tocophérol
EP0565007B1 (fr) * 1992-04-10 1998-07-08 Senju Pharmaceutical Co., Ltd. Composition de bain
WO2002026238A1 (fr) * 2000-09-26 2002-04-04 Vital Health Sciences Pty Ltd. Supplements a base de derive phosphate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2854631B2 (ja) * 1989-11-21 1999-02-03 千寿製薬株式会社 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
FR2715565B1 (fr) * 1994-01-31 1996-03-15 Oreal Composition cosmétique ou dermatologique stabilisée contenant plusieurs précurseurs d'un même actif pour maximaliser sa libération, son utilisation.
JPH1143436A (ja) * 1997-07-25 1999-02-16 Showa Denko Kk 末梢血流障害予防・治療剤
US5776915A (en) * 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
JP3950216B2 (ja) * 1997-12-26 2007-07-25 日本メナード化粧品株式会社 皮膚外用剤

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5603949A (en) * 1991-08-01 1997-02-18 Lvmh Recherche Use of a tocopherol phosphate or one of its derivatives, for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
US5643597A (en) * 1991-08-01 1997-07-01 Lvmh Recherche Use of a tocopherol phosphate or one of its derivatives for the preparation of cosmetic or pharmaceutical compositions and compositions so obtained
WO1993015731A1 (fr) * 1992-02-14 1993-08-19 Robert Lamb Derives de phosphate de vitamine e pour la protection des cellules
EP0565007B1 (fr) * 1992-04-10 1998-07-08 Senju Pharmaceutical Co., Ltd. Composition de bain
EP0684043A1 (fr) * 1994-04-28 1995-11-29 Senju Pharmaceutical Co., Ltd. Composition thérapeutique pour les altéreations de la cornée contenant un diester de l'acide phosphonique
EP0845216A1 (fr) * 1996-11-27 1998-06-03 Showa Denko Kabushiki Kaisha Composition destinée à être administrée aux animaux et contenant un phosphate de tocophérol
WO2002026238A1 (fr) * 2000-09-26 2002-04-04 Vital Health Sciences Pty Ltd. Supplements a base de derive phosphate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1429782A4 *

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841342B2 (en) 2002-08-09 2014-09-23 Vital Health Sciences Pty. Ltd. Carrier
WO2004064831A1 (fr) * 2003-01-17 2004-08-05 Vital Health Sciences Pty Ltd Composes possedant des proprietes antiproliferatives
EP1720551A1 (fr) * 2004-03-03 2006-11-15 Vital Health Sciences Pty Ltd. Formulations alcaloides
EP1720551A4 (fr) * 2004-03-03 2007-04-04 Vital Health Sciences Pty Ltd Formulations alcaloides
JP2007526256A (ja) * 2004-03-03 2007-09-13 バイタル ヘルス サイエンシズ プロプライアタリー リミティド アルカロイド製剤
JP4847437B2 (ja) * 2004-03-03 2011-12-28 バイタル ヘルス サイエンシズ プロプライアタリー リミティド アルカロイド製剤
US20090004166A1 (en) * 2004-08-03 2009-01-01 Simon Michael West Carrier For Enternal Administration
WO2006092025A1 (fr) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Composés ayant des propriétés d’abaissement des lipides
WO2006092024A1 (fr) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Composés ayant des propriétés anticancéreuses
JP2008531603A (ja) * 2005-03-03 2008-08-14 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 脂質低下特性を有する化合物
AU2006220248B2 (en) * 2005-03-03 2012-06-21 Vital Health Sciences Pty Ltd Compounds having lipid lowering properties
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
WO2011094822A1 (fr) * 2010-02-05 2011-08-11 Phosphagenics Limited Composition de support
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
US10188670B2 (en) 2011-03-15 2019-01-29 Phosphagenics Limited Composition
US10973761B2 (en) 2015-12-09 2021-04-13 Phosphagenics Limited Pharmaceutical formulation
US11753435B2 (en) 2016-12-21 2023-09-12 Avecho Biotechnology Limited Process

Also Published As

Publication number Publication date
EP1429782A1 (fr) 2004-06-23
EP1429782A4 (fr) 2005-02-02
CA2458279A1 (fr) 2003-04-03
JP2005515969A (ja) 2005-06-02
MXPA04001779A (es) 2004-05-31

Similar Documents

Publication Publication Date Title
US20040241225A1 (en) Modulation of vitamin storage
US5198432A (en) Method of preventing chlorohydrocarbon toxicity using sterol derivatives
US9789127B2 (en) N-acyl-phosphatidyl-ethanolamines and/or mixtures of N-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
EP1429782A1 (fr) Modulation du stockage de vitamines
EP1896489B1 (fr) Sels ou complexes de donneurs de groupes méthyle avec de l acide phytique ou ses dérivés et procédé pour leur synthèse
Gross et al. Seven day oral supplementation with Cardax TM (disodium disuccinate astaxanthin) provides significant cardioprotection and reduces oxidative stress in rats
Adachi et al. Intragastrically administered lysophosphatidic acids protect against gastric ulcer in rats under water-immersion restraint stress
CA2601641A1 (fr) Sel de calcium de myo-inositol 1,6:2,3:4,5 tripyrophosphate utile comme effecteur allosterique de l'hemoglobine
US20050009787A1 (en) Micronutrient phosphates as dietary and health supplements
MXPA03003584A (es) Formulacion que contiene derivados de fosfato de agentes de transferencia de electrones.
US5610180A (en) Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
RU2432169C2 (ru) Фосфолипидные комплексы из экстрактов листьев или плодов маслины, обладающие улучшенной биодоступностью
JPH02191220A (ja) イノシトールトリホスフェートを含有するリポ蛋白質の異常レベルに対する医薬
Turunen et al. Blood concentration of coenzyme Q10 increases in rats when esterified forms are administered
Liu et al. Nutrimetabolomic analysis provides new insights into spermine-induced ileum-system alterations for suckling rats
WO2005099739A1 (fr) Chromoproteines dibenzo-alpha-pyrone oxygenees
AU2002333019B2 (en) Modulation of vitamin storage
AU2002333019A1 (en) Modulation of vitamin storage
ZA200401126B (en) Modulation of vitamin storage.
Kalén et al. The effects of inducers of the endoplasmic reticulum, peroxisomes and mitochondria on the amounts and synthesis of ubiquinone in rat liver subcellular membranes
US7033612B2 (en) Composition and method for treating age-related disorders
Matsuda et al. Phospholipid composition of cardiac (Na++ K+)-ATPases from various species
AU2002322163A1 (en) Micronutrient phosphates as dietary and health supplements
WO2009145751A1 (fr) Sel calcique/sodique de tripyrophosphate d'inositol utilisable en tant qu'effecteur allostérique de l'hémoglobine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2002333019

Country of ref document: AU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004/01126

Country of ref document: ZA

Ref document number: 200401126

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2458279

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10487743

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/001779

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002799356

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003530308

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002799356

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002333019

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 2002799356

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002799356

Country of ref document: EP